A University of Alabama at Birmingham biotech startup received $1.2 million to continue research toward treating a chronic kidney disease.

Reliant Glycosciences LLC received a National Institutes of Health Small Business Innovation Research Phase II award to continue the development of its IgA nephropathy-related biomarker assays. The award runs through spring 2024.

Read full article HERE.